🎉 M&A multiples are live!
Check it out!

Agenus Valuation Multiples

Discover revenue and EBITDA valuation multiples for Agenus and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Agenus Overview

About Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).


Founded

1999

HQ

United States of America
Employees

316

Website

agenusbio.com

Financials

LTM Revenue $104M

LTM EBITDA n/a

EV

$99.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Agenus Financials

Agenus has a last 12-month revenue of $104M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Agenus achieved revenue of $103M and an EBITDA of -$101M.

Agenus expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Agenus valuation multiples based on analyst estimates

Agenus P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $156M $103M XXX XXX XXX
Gross Profit -$99.2M -$81.4M XXX XXX XXX
Gross Margin -63% -79% XXX XXX XXX
EBITDA -$146M -$101M XXX XXX XXX
EBITDA Margin -93% -98% XXX XXX XXX
Net Profit -$220M -$246M XXX XXX XXX
Net Margin -141% -238% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Agenus Stock Performance

As of April 15, 2025, Agenus's stock price is $2.

Agenus has current market cap of $45.0M, and EV of $99.5M.

See Agenus trading valuation data

Agenus Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$99.5M $45.0M XXX XXX XXX XXX $-8.83

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Agenus Valuation Multiples

As of April 15, 2025, Agenus has market cap of $45.0M and EV of $99.5M.

Agenus's trades at 1.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Agenus's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Agenus and 10K+ public comps

Agenus Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $99.5M XXX XXX XXX
EV/Revenue 1.0x XXX XXX XXX
EV/EBITDA -1.0x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Agenus Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Agenus Valuation Multiples

Agenus's NTM/LTM revenue growth is 3%

Agenus's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, Agenus's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Agenus's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Agenus and other 10K+ public comps

Agenus Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -34% XXX XXX XXX XXX
EBITDA Margin -98% XXX XXX XXX XXX
EBITDA Growth -31% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -95% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 69% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 69% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Agenus Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Agenus M&A and Investment Activity

Agenus acquired  XXX companies to date.

Last acquisition by Agenus was  XXXXXXXX, XXXXX XXXXX XXXXXX . Agenus acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Agenus

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Agenus

When was Agenus founded? Agenus was founded in 1999.
Where is Agenus headquartered? Agenus is headquartered in United States of America.
How many employees does Agenus have? As of today, Agenus has 316 employees.
Who is the CEO of Agenus? Agenus's CEO is Dr. Garo H. Armen, PhD.
Is Agenus publicy listed? Yes, Agenus is a public company listed on NAS.
What is the stock symbol of Agenus? Agenus trades under AGEN ticker.
When did Agenus go public? Agenus went public in 2000.
Who are competitors of Agenus? Similar companies to Agenus include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Agenus? Agenus's current market cap is $45.0M
What is the current revenue of Agenus? Agenus's last 12-month revenue is $104M.
What is the current EV/Revenue multiple of Agenus? Current revenue multiple of Agenus is 1.0x.
What is the current revenue growth of Agenus? Agenus revenue growth between 2023 and 2024 was -34%.
Is Agenus profitable? Yes, Agenus is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.